Investor Presentaiton

BEGONIA Arm 7: Dato-DXd + Durvalumab Adverse Events Most frequently reported adverse events (≥15%) (N=62) The most common AEs were gastrointestinal and generally of low grade (Table) AE preferred term Any grade, n (%) Grade 3/4, n (%) Nausea 40 (65) 0 Stomatitis 40 (65) 7 (11) Alopecia 31 (50) 0 Constipation 29 (47) 1 (2) Fatigue 28 (45) Rash 20 (32) 1 (2) 0 Vomiting 16 (26) 1 (2) Amylase increased 13 (21) 11 (18) COVID-19 13 (21) 0 Dry eye 13 (21) 0 Decreased appetite 12 (19) 1 (2) Pruritus 10 (16) 0 Cough 10 (16) 0 AE, adverse event; AESI, adverse event of special interest; ILD, interstitial lung disease. Stomatitis was the most common AE leading to Dato-DXd dose reduction (11 patients) There were 3 (5%) adjudicated treatment-related ILD/pneumonitis events (2 grade 2 events, 1 grade 1 event) Limited rates of diarrhea (13% any grade, 1 grade 3 event) and neutropenia (5% any grade, 1 grade 3 event) were reported The most frequent AESIS for Arm 7 were stomatitis (65%), rash (32%), dry eye (21%), hypothyroidism (14.5%), and keratitis (14.5%) Daiichi-Sankyo Data cutoff: 02 Feb 2023 42

View entire presentation